Introduction: Highly effective malaria vaccines are essential component toward malaria elimination. Although the leading malaria vaccine, RTS,S/AS01, with modest efficacy is being evaluated in a pilot feasibility trial, development of a malaria transmission-blocking vaccine (TBV) could make a major contribution toward malaria elimination. Only a few TBV antigens have reached pre-clinical or clinical development but with several challenges including difficulties in the expression of malaria recombinant proteins and low immunogenicity in humans. Therefore, novel approaches to accelerate TBV research to preclinical development are critical to generate an efficacious TBV.Areas covered: PubMed was searched to review the progress and future prospects of malaria TBV research and development. We also reviewed registered trials at ClinicalTrials.gov as well as post-genome TBV candidate discovery research including our efforts.Expert opinion: Wheat germ cell-free protein synthesis technology can accelerate TBV development by overcoming some current challenges of TBV research.

中文翻译：

---

阻止疟疾传播的疫苗：无小麦生殖细胞技术可以加速疫苗的开发。

简介：高效的疟疾疫苗是消除疟疾的重要组成部分。尽管在一项可行性试验中正在评估效力不高的领先疟疾疫苗RTS，S / AS01，但开发阻止疟疾传播的疫苗（TBV）可能对消除疟疾做出重大贡献。仅少数TBV抗原已达到临床前或临床开发，但面临一些挑战，包括在疟疾重组蛋白表达方面的困难和人类免疫原性低。因此，加快TBV研究到临床前发展的新方法对于产生有效的TBV至关重要。研究范围：搜索PubMed以回顾疟疾TBV研究与开发的进展和未来前景。我们还审查了ClinicalTrials的注册试验。